MA34771B1 - Formes cristallines - Google Patents

Formes cristallines

Info

Publication number
MA34771B1
MA34771B1 MA36066A MA36066A MA34771B1 MA 34771 B1 MA34771 B1 MA 34771B1 MA 36066 A MA36066 A MA 36066A MA 36066 A MA36066 A MA 36066A MA 34771 B1 MA34771 B1 MA 34771B1
Authority
MA
Morocco
Prior art keywords
varieties
modulation
sensitive
cells
determining
Prior art date
Application number
MA36066A
Other languages
Arabic (ar)
English (en)
Inventor
Lili Feng
Baoqing Gong
Piotr H Karpinski
Liladhar Murlidhar Waykole
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45464892&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA34771(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA34771B1 publication Critical patent/MA34771B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La présente invention concerne des formes cristallines spécifiques de la 5 -chloro-n-(2-isopropoxy-5-méthyl-4-(pipéridin-4-ylphényl)-n-2-(isopropylsulfonyl)phényl)-2,4-diamine. La présente invention concerne en outre des procédés de préparation desdites formes cristallines, des compositions pharmaceutiques comprenant lesdites formes cristallines, et des procédés d'utilisation desdites formes cristallines et des compositions pharmaceutiques pour traiter une maladie.
MA36066A 2010-12-17 2013-06-28 Formes cristallines MA34771B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201061424194P 2010-12-17 2010-12-17
PCT/US2011/065030 WO2012082972A1 (fr) 2010-12-17 2011-12-15 Formes cristallines de la 5-chloro-n2-(2-isopropoxy-5-méthyl-4-pipéridin-4-yl-phényl)-n4[2-(propane-2-sulfonyl)-phényl]-pyrimidine-2,4-diamine

Publications (1)

Publication Number Publication Date
MA34771B1 true MA34771B1 (fr) 2013-12-03

Family

ID=45464892

Family Applications (1)

Application Number Title Priority Date Filing Date
MA36066A MA34771B1 (fr) 2010-12-17 2013-06-28 Formes cristallines

Country Status (36)

Country Link
US (2) US9309229B2 (fr)
EP (3) EP3453708B8 (fr)
JP (1) JP5916752B2 (fr)
KR (4) KR20130130022A (fr)
CN (7) CN112125884A (fr)
AR (2) AR084309A1 (fr)
AU (1) AU2011343775B2 (fr)
BR (1) BR112013015000A2 (fr)
CA (1) CA2821102C (fr)
CL (1) CL2013001723A1 (fr)
CO (1) CO6801792A2 (fr)
CY (2) CY1119474T1 (fr)
DK (2) DK2651918T3 (fr)
EC (1) ECSP13012770A (fr)
ES (3) ES2696526T3 (fr)
GT (1) GT201300153A (fr)
HR (2) HRP20171477T1 (fr)
HU (1) HUE041845T2 (fr)
IL (1) IL226474A (fr)
LT (2) LT2651918T (fr)
MA (1) MA34771B1 (fr)
MX (1) MX338210B (fr)
MY (2) MY177742A (fr)
NZ (1) NZ610713A (fr)
PE (1) PE20140698A1 (fr)
PH (1) PH12013501254A1 (fr)
PL (2) PL2651918T3 (fr)
PT (2) PT2651918T (fr)
RS (1) RS57771B1 (fr)
RU (2) RU2599785C3 (fr)
SG (2) SG10201510082XA (fr)
SI (2) SI2651918T1 (fr)
TN (1) TN2013000216A1 (fr)
TW (2) TWI576344B (fr)
WO (1) WO2012082972A1 (fr)
ZA (1) ZA201303599B (fr)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112013015000A2 (pt) * 2010-12-17 2016-08-09 Novartis Ag formas cristalinas de 5-cloron2-(2-isopropóxi-5-metil-4-piperidin-4-il-fenil)-n4-[2-(propano-2-sulfonil)-fenil]-pirimidina-2,4-diamina
CN104854101B (zh) 2012-11-06 2018-05-01 上海复尚慧创医药研究有限公司 Alk激酶抑制剂
KR101656382B1 (ko) * 2014-02-28 2016-09-09 한국화학연구원 피리미딘-2,4-디아민 유도체 및 이를 유효성분으로 함유하는 항암용 약학적 조성물
CN105272921A (zh) * 2014-06-09 2016-01-27 江苏奥赛康药业股份有限公司 一种制备Ceritinib的方法及其中间体化合物
CN105294649B (zh) * 2014-07-30 2019-05-14 江苏奥赛康药业股份有限公司 一种Ceritinib化合物及其药物组合物
CN105294650A (zh) * 2014-08-01 2016-02-03 江苏奥赛康药业股份有限公司 一种Ceritinib化合物及其药物组合物
UA119794C2 (uk) 2014-10-21 2019-08-12 Аріад Фармасьютикалз, Інк. Кристалічна форма 5-хлор-n4-[2-(диметилфосфорил)феніл]-n2-{2-метокси-4-[4-(4-метилпіперазин-1-іл)піперидин-1-іл]}піримідин-2,4-діаміну
WO2016081538A1 (fr) 2014-11-18 2016-05-26 Teva Pharmaceuticals International Gmbh Formes solides de ceritinib et sels de ceux-ci
CN105601614A (zh) * 2014-11-21 2016-05-25 奥浦顿（上海）医药科技有限公司 一种色瑞替尼晶型及其制备方法
WO2016082795A1 (fr) * 2014-11-28 2016-06-02 苏州晶云药物科技有限公司 Forme cristalline i du ceritinib et son procédé de préparation
CN105622577A (zh) * 2014-11-29 2016-06-01 江苏先声药业有限公司 一种色瑞替尼的新晶型及其制备方法
WO2016108123A2 (fr) * 2014-12-17 2016-07-07 Dr. Reddy’S Laboratories Limited Forme amorphe pure et dispersion solide amorphe de céritinib
WO2016098070A1 (fr) 2014-12-19 2016-06-23 Novartis Ag Forme cristalline de la 5-chloro-n2-(2-isopropoxy-5-méthyl-4-pipéridin-4-yl-phényl)-n4-[2-(propane-2-sulfonyl)-phényl]-pyrimidine-2,4-diamine
WO2016098042A1 (fr) * 2014-12-19 2016-06-23 Novartis Ag Utilisation du céritinib (ldk -378) dans le traitement de troubles médiés par fes ou fer, en particulier des troubles prolifératifs
WO2017016529A1 (fr) 2015-07-28 2017-02-02 Zentiva, K.S. Formes solides de ceritinib base libre
CN105061397B (zh) * 2015-08-07 2018-01-02 武汉英普瑞医药科技有限公司 一种色瑞替尼的c型晶型及其制备方法与应用
CN106699743B (zh) 2015-11-05 2020-06-12 湖北生物医药产业技术研究院有限公司 嘧啶类衍生物及其用途
WO2017152858A1 (fr) * 2016-03-11 2017-09-14 苏州晶云药物科技有限公司 Forme cristalline de céritinib et procédé pour sa préparation
WO2017158619A1 (fr) 2016-03-15 2017-09-21 Natco Pharma Limited Procédé modifié pour la préparation de céritinib et de forme amorphe de céritinib
JP2019196359A (ja) * 2019-06-17 2019-11-14 ノバルティス アーゲー ピリミジン誘導体およびそれらの中間体を調製する化学的方法
GB201915618D0 (en) 2019-10-28 2019-12-11 Univ Oslo ALK inhibitors for treatment of ALK-negative cancer and antibody-mediated diseases
CN113135905B (zh) 2020-01-17 2023-11-21 轩竹生物科技股份有限公司 多环类间变性淋巴瘤激酶抑制剂的晶型
US12583835B2 (en) * 2020-03-30 2026-03-24 Jiangsu Yahong Meditech Co., Ltd. Crystal form of nitroxoline prodrug, pharmaceutical composition containing same, and preparation method therefor and application thereof
TW202508595A (zh) 2023-05-04 2025-03-01 美商銳新醫藥公司 用於ｒａｓ相關疾病或病症之組合療法
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2025171296A1 (fr) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Inhibiteurs de ras
TW202547461A (zh) 2024-05-17 2025-12-16 美商銳新醫藥公司 Ｒａｓ抑制劑
WO2025255438A1 (fr) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Procédés de traitement d'une maladie ou d'un trouble lié à la protéine ras
WO2025265060A1 (fr) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Compositions thérapeutiques et procédés de gestion d'effets liés au traitement
WO2026006747A1 (fr) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Inhibiteurs de ras
WO2026015796A1 (fr) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Méthodes de traitement d'une maladie ou d'un trouble lié à ras
WO2026015790A1 (fr) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Méthodes de traitement d'une maladie ou d'un trouble lié à ras
WO2026015801A1 (fr) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Méthodes de traitement d'une maladie ou d'un trouble liés à ras
WO2026015825A1 (fr) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Utilisation d'un inhibiteur de ras pour traiter le cancer du pancréas
WO2026050446A1 (fr) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Inhibiteurs de ras
WO2026072904A2 (fr) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions et méthodes de traitement du cancer du poumon

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0206215D0 (en) 2002-03-15 2002-05-01 Novartis Ag Organic compounds
PT1660458E (pt) * 2003-08-15 2012-04-27 Novartis Ag 2,4-pirimidinodiaminas úteis no tratamento de doenças neoplásicas, desordens inflamatórias e do sistema imunitário
GB0419161D0 (en) * 2004-08-27 2004-09-29 Novartis Ag Organic compounds
NZ577197A (en) 2006-12-08 2011-02-25 Irm Llc Pyrimidine compounds especially 4-phenylamino-2-arylamino-pyrimidine derivatives and compositions as protein kinase inhibitors
EA017405B9 (ru) 2006-12-08 2014-05-30 АйАрЭм ЭлЭлСи Соединения и композиции в качестве ингибиторов протеинкиназы
EA017252B1 (ru) * 2007-08-28 2012-11-30 Айрм Ллк Производные 2-бифениламино-4-аминопиримидина в качестве ингибиторов киназ
AU2008296479A1 (en) * 2007-08-28 2009-03-12 Dana Farber Cancer Institute Amino substituted pyrimidine, pyrollopyridine and pyrazolopyrimidine derivatives useful as kinase inhibitors and in treating proliferative disorders and diseases associated with angiogenesis
MX2010010968A (es) * 2008-04-07 2010-10-26 Irm Llc Compuestos y composiciones como inhibidores de cinasa de proteina.
MX353308B (es) * 2008-05-21 2018-01-08 Ariad Pharma Inc Derivados fosforosos como inhibidores de cinasa.
CA2763717A1 (fr) * 2009-06-10 2010-12-16 Cellzome Limited Derives de pyrimidine comme inhibiteurs de la zap-70
TWI481607B (zh) 2009-12-17 2015-04-21 Lundbeck & Co As H 作為ｐｄｅ１０ａ酵素抑制劑的２－芳基咪唑衍生物
CN103596929B (zh) 2010-12-17 2016-10-19 里亚塔医药公司 作为抗氧化发炎调节剂的吡唑及嘧啶三环烯酮
BR112013015000A2 (pt) * 2010-12-17 2016-08-09 Novartis Ag formas cristalinas de 5-cloron2-(2-isopropóxi-5-metil-4-piperidin-4-il-fenil)-n4-[2-(propano-2-sulfonil)-fenil]-pirimidina-2,4-diamina
WO2012082580A2 (fr) 2010-12-17 2012-06-21 E. I. Du Pont De Nemours And Company Amides azocycliques fongicides
CN105294650A (zh) 2014-08-01 2016-02-03 江苏奥赛康药业股份有限公司 一种Ceritinib化合物及其药物组合物
WO2016081538A1 (fr) 2014-11-18 2016-05-26 Teva Pharmaceuticals International Gmbh Formes solides de ceritinib et sels de ceux-ci
DE112015005255B4 (de) 2014-11-21 2023-10-26 Joyson Safety Systems Acquisition Llc Airbagmodul
CN105622577A (zh) 2014-11-29 2016-06-01 江苏先声药业有限公司 一种色瑞替尼的新晶型及其制备方法
EP3227335A1 (fr) 2014-12-04 2017-10-11 Bristol-Myers Squibb Company Combinaison d'anticorps anti-cs1 et anti-pd1 pour traiter le cancer (myélome)
WO2016098070A1 (fr) 2014-12-19 2016-06-23 Novartis Ag Forme cristalline de la 5-chloro-n2-(2-isopropoxy-5-méthyl-4-pipéridin-4-yl-phényl)-n4-[2-(propane-2-sulfonyl)-phényl]-pyrimidine-2,4-diamine
WO2017016529A1 (fr) 2015-07-28 2017-02-02 Zentiva, K.S. Formes solides de ceritinib base libre
CN105061397B (zh) 2015-08-07 2018-01-02 武汉英普瑞医药科技有限公司 一种色瑞替尼的c型晶型及其制备方法与应用

Also Published As

Publication number Publication date
US20130274279A1 (en) 2013-10-17
PH12013501254A1 (en) 2016-07-29
CA2821102C (fr) 2019-06-11
US20160175305A1 (en) 2016-06-23
ZA201303599B (en) 2014-02-26
WO2012082972A1 (fr) 2012-06-21
HRP20171477T1 (hr) 2017-11-17
AR122395A2 (es) 2022-09-07
TWI576344B (zh) 2017-04-01
ECSP13012770A (es) 2013-10-31
EP3121171B1 (fr) 2018-08-15
SI3121171T1 (sl) 2018-11-30
TW201629021A (zh) 2016-08-16
RU2016136823A (ru) 2018-12-11
DK3121171T3 (en) 2018-12-10
CN104262324A (zh) 2015-01-07
CO6801792A2 (es) 2013-11-29
US9309229B2 (en) 2016-04-12
PT3121171T (pt) 2018-11-27
HRP20181737T1 (hr) 2018-12-28
GT201300153A (es) 2014-06-09
BR112013015000A2 (pt) 2016-08-09
KR20180032680A (ko) 2018-03-30
JP5916752B2 (ja) 2016-05-11
MX338210B (es) 2016-04-07
CN103282359A (zh) 2013-09-04
AR084309A1 (es) 2013-05-08
EP2651918B1 (fr) 2017-07-12
DK2651918T3 (en) 2017-10-23
RS57771B1 (sr) 2018-12-31
CY1119474T1 (el) 2018-04-04
IL226474A (en) 2016-03-31
TWI576343B (zh) 2017-04-01
LT2651918T (lt) 2017-10-10
PL2651918T3 (pl) 2017-12-29
RU2746159C2 (ru) 2021-04-08
AU2011343775B2 (en) 2015-12-03
CY1121017T1 (el) 2019-12-11
SG10201510082XA (en) 2016-01-28
CA2821102A1 (fr) 2012-06-21
PE20140698A1 (es) 2014-06-11
PL3121171T3 (pl) 2019-01-31
HUE041845T2 (hu) 2019-05-28
EP3453708B8 (fr) 2022-03-16
IL226474A0 (en) 2013-07-31
JP2013545812A (ja) 2013-12-26
EP2651918A1 (fr) 2013-10-23
LT3121171T (lt) 2018-11-12
RU2599785C3 (ru) 2019-04-24
KR20190022903A (ko) 2019-03-06
EP3453708B1 (fr) 2021-10-27
MY164810A (en) 2018-01-30
CN107056751A (zh) 2017-08-18
KR102325775B1 (ko) 2021-11-12
RU2599785C2 (ru) 2016-10-20
SI2651918T1 (sl) 2017-10-30
RU2016136823A3 (fr) 2020-02-06
KR20200039021A (ko) 2020-04-14
CN106831716A (zh) 2017-06-13
AU2011343775A1 (en) 2013-07-18
PT2651918T (pt) 2017-10-17
EP3453708A1 (fr) 2019-03-13
CN114989139A (zh) 2022-09-02
RU2013132947A (ru) 2015-01-27
CL2013001723A1 (es) 2013-12-27
MY177742A (en) 2020-09-23
ES2696526T3 (es) 2019-01-16
KR20130130022A (ko) 2013-11-29
CN112125884A (zh) 2020-12-25
ES2643016T3 (es) 2017-11-21
TW201307299A (zh) 2013-02-16
MX2013006952A (es) 2013-07-15
ES2905973T3 (es) 2022-04-12
TN2013000216A1 (en) 2014-11-10
SG190856A1 (en) 2013-07-31
NZ610713A (en) 2014-10-31
CN106008462A (zh) 2016-10-12
EP3121171A1 (fr) 2017-01-25

Similar Documents

Publication Publication Date Title
MA34771B1 (fr) Formes cristallines
MA33208B1 (fr) Anticorps anti-fgfr3 et procédés d'utilisation de ceux-ci
MA32351B1 (fr) Derives d'aminodihydrothiazine a titre d'inhibiteurs de bace pour le traitement de la maladie d'alzheimer
PH12012500809A1 (en) Methods and compositions for treating cancer
EP2410330A3 (fr) Procédés d'utilisation du récepteur GPR119 permettant d'identifier les composants utiles à l'augmentation de la masse osseuse chez un individu
MA40249A (fr) Modulateurs des récepteurs d'aryle, et leurs procédés de fabrication et méthodes d'utilisation
MA33450B1 (fr) Dérivés d'oxazine et leur utilisation en tant qu'inhibiteurs de bace pour le traitement de troubles neurologiques
TW200634006A (en) Tetrahydroquinoline analogues as muscarinic agonists
MA34299B1 (fr) Dérivés d'aminopyrimidine au titre de modulateurs de lrrk2
MA34069B1 (fr) Dérivés de n-(imidazopyrimidin-7-yl)hétéroarylamide et leur utilisation comme inhibiteurs de pde10a)
MA30672B1 (fr) Utilisation de derives de l'azabicyclo hexane
TW200621722A (en) 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones, 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds
EA201070148A1 (ru) Соединения и способы модулирования фарнезоидного рецептора x (fxr)
EA200800727A1 (ru) Введение ингибиторов дипептидилпептидазы
MA33419B1 (fr) Composés et compositions pour le traitement de maladies parasitaires
EA201270535A1 (ru) Пуриновые производные, применимые в качестве ингибиторов hsp90
EP1740559A4 (fr) Derives de phenyle 1,3,5-substitues utiles comme inhibiteurs de la beta-secretase pour le traitement de la maladie d'alzheimer
MA39972B1 (fr) Composés et compositions d'induction de la chondrogenèse
MA33839B1 (fr) Compositions et procédés destinés à diagnostiquer et à traiter des tumeurs
MA39163A1 (fr) Forme cristalline de (s)-(2-(6-chloro-7-methyl-1h-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1 -yl)(5-methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone et utilisation de celle-ci en tant qu'antagonistes des recepteurs de l'orexine
MA39164B1 (fr) Forme de sel cristalline de (s)-(2-(6-chloro-7-méthyl-1 h-benzo[d]imidazol- 2-yl)-2-méthylpyrrolidin-1-yl)(5-méthoxy-2-(2h-1,2,3-triazol-2-yl)phényl)méthanone comme antagoniste des récepteurs à l'oréxine
WO2006102308A3 (fr) Antagonistes de bêta-lactamyl vasopressine v1b
WO2011008572A3 (fr) Modulateurs du récepteur 5-ht3, procédés de fabrication et d'utilisation de ceux-ci
MX2018001979A (es) (s,e) -3- (6-aminopiridin-3-il) -n- ( (5- (4- (3-fluoruro-3 metilpirrolidin-1-carbonil) fenil) -7- (4 fluorofenil) benzofuran-2-il)metil)acrilamida para el tratamiento del cancer.
UA83868C2 (ru) Производные бензимидазолона и хиназолинона в качестве агонистов человеческих рецепторов orl1